|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2001-10-10
|
|
pubmed:abstractText |
Oral administration of penclomedine was investigated based on preclinical studies indicating that an oral schedule of penclomedine treatment may prevent the neurotoxicity observed in phase I studies of an intravenous (i.v.) formulation, possibly by reducing maximum plasma concentrations (Cmax) of the neurotoxic parent species.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
223-8
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11592344-Administration, Oral,
pubmed-meshheading:11592344-Adult,
pubmed-meshheading:11592344-Aged,
pubmed-meshheading:11592344-Antineoplastic Agents,
pubmed-meshheading:11592344-Area Under Curve,
pubmed-meshheading:11592344-Biological Availability,
pubmed-meshheading:11592344-Chromatography, High Pressure Liquid,
pubmed-meshheading:11592344-Drug Administration Routes,
pubmed-meshheading:11592344-Drug Administration Schedule,
pubmed-meshheading:11592344-Humans,
pubmed-meshheading:11592344-Infusions, Intravenous,
pubmed-meshheading:11592344-Maximum Tolerated Dose,
pubmed-meshheading:11592344-Metabolic Clearance Rate,
pubmed-meshheading:11592344-Middle Aged,
pubmed-meshheading:11592344-Neoplasms,
pubmed-meshheading:11592344-Picolines
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine.
|
|
pubmed:affiliation |
The Johns Hopkins Oncology Center, Baltimore, MD 21287-8934, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.
|
